These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15629358)

  • 1. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.
    Steinberg T; Ohlschläger P; Sehr P; Osen W; Gissmann L
    Vaccine; 2005 Jan; 23(9):1149-57. PubMed ID: 15629358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
    Dell K; Klein C; Gissmann L
    Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
    Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
    Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein.
    Smahel M; Poláková I; Pokorná D; Ludvíková V; Dusková M; Vlasák J
    Int J Oncol; 2008 Jul; 33(1):93-101. PubMed ID: 18575754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
    Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
    Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
    J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase.
    Smahel M; Pokorná D; Macková J; Vlasák J
    J Gene Med; 2004 Oct; 6(10):1092-101. PubMed ID: 15386741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
    Smahel M; Síma P; Ludvíková V; Vonka V
    Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate.
    Meshkat Z; Soleimanjahi H; Mahmoudi M; Hassan ZM; Mirshahabi H; Meshkat M; Kheirandish M
    Iran J Immunol; 2008 Jun; 5(2):82-91. PubMed ID: 18523353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
    Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
    Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
    Routes JM; Ryan S; Li H; Steinke J; Cook JL
    Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.